Статья
Практические аспекты оказания помощи пациентам с кардиогенным шоком
Кардиогенный шок является ведущей причиной смертности среди пациентов с острым коронарным синдромом, для данной патологии характерны высокие показатели внутрибольничной и годовой летальности. В отечественной литературе данные по распространенности, диагностике и лечению пациентов с кардиогенным шоком ограничены, поэтому основной целью данной публикации является повышение информированности специалистов о современных подходах к диагностике и лечению этого состояния. В данном обзоре подробно рассматриваются основные причины развития кардиогенного шока, аспекты патофизиологии, современная классификация, диагностика и алгоритмы медикаментозной и немедикаментозной терапии пациентов с истинным кардиогенным шоком.
1. Laslett L, Alagona P, Clark B, et al. The worldwide environment of cardiovascular disease: Prevalence, diagnosis, therapy, and policy issues. Journal of the American College of Cardiology. 2012;60(25):1-49. doi:10.1016/j.jacc.2012.11.002.
2. Bauersachs R, Zeymer U, Brière J, et al. Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review. Cardiovasc Therapy. 2019;2019:26:e8295054. doi:10.1155/2019/8295054.
3. Malakar A, Choudhury D, Halder B, et al. A review on coronary artery disease, its risk factors, and therapeutics. Journal of Cellular Physiology. 2019;234(10):16812-23. doi:10.1002/jcp.28350.
4. Chioncel O, Parissis J, Mebazaa A, et al. Epidemiology, pathophysiology and contemporary management of cardiogenic shock — a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22(8):1315-41. doi:10.1002/ejhf.1922.
5. Babaev A, Frederick PD, Pasta DJ, et al. Trends in Management and Outcomes of Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. JAMA. 2005;294(4):448-54. doi:10.1001/jama.294.4.448.
6. Shah M, Patnaik S, Patel B, et al. Trends in mechanical circulatory support use and hospital mortality among patients with acute myocardial infarction and non-infarction related cardiogenic shock in the United States. Clinical Research in Cardiology. 2018;107(4):287-303. doi:10.1007/s00392-017-1182-2.
7. Berg D, Bohula E, Diepen S, et al. Epidemiology of Shock in Contemporary Cardiac Intensive Care Units: Data from the Critical Care Cardiology Trials Network Registry. Circ Cardiovasc Qual Outcomes. 2019;12(3):e005618. doi:10.1161/CIRCOUTCOMES.119.005618.
8. Wan M, Qian S, Huang Y, et al. Drug Discovery for Coronary Artery Disease. In: Wang, M. (eds) Coronary Artery Disease: Therapeutics and Drug Discovery. Advances in Experimental Medicine and Biology. 2020;1177:297-339; Springer, Singapore. doi:10.1007/978-981-15-2517-9_8.
9. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: Epidemiological update. Eur Heart J. 2014;35(42):2950-9. doi:10.1093/eurheartj/ehu299.
10. Драпкина О.М., Куценко В.А., Шальнова С.А. и др. Инфаркт миокарда в популяции некоторых регионов России и его прогностическое значение. Российский кардиологический журнал. 2022;27(6):4952. doi:10.15829/1560-4071-2022-4952.
11. Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. The Lancet. 2017;389(10065):197-210. doi:10.1016/S0140-6736(16)30677-8.
12. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction. European Heart Journal. 2019;40(3):237-69. doi:10.1093/eurheartj/ehy462.
13. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal. 2018;39(2):119-77. doi:10.1093/eurheartj/ehx393.
14. Velagaleti RS, Pencina MJ, Murabito JM. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation. 2008;118(20):2057-62. doi:10.1161/CIRCULATIONAHA.108.784215.
15. Бойцов С.А., Акчурин Р.С., Певзнер Д.В. и др. Кардиогенный шок — современное состояние проблемы. Российский кардиологический журнал, 2019;(10):126-36. doi:10.15829/1560-4071-2019-10-126-136.
16. Thiele H, Ohman EM, de Waha-Thiele S, et al. Management of cardiogenic shock complicating myocardial infarction: An update 2019. European Heart Journal. 2019;40(32):2671-83. doi:10.1093/eurheartj/ehz363.
17. Furer A, Wessler J, Burkhoff D. Hemodynamics of Cardiogenic Shock. Interventional Cardiology Clinics. 2017;6(3):359-71. doi:10.1016/j.iccl.2017.03.006.
18. Baran D, Grines L, Bailey S, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheterization and Cardiovascular Interventions. 2019;94(1):29-37. doi:10.1002/ccd.28329.
19. Лысенко М.А., Кецкало М.В. Столичное здравоохранение в призме глобального лидерства: Сборник докладов II научно-методического форума организаторов здравоохранения с международным участием, Москва, 10-11 декабря 2020 года. Москва: Государственное бюджетное учреждение города Москвы "Научно-исследовательский институт организации здравоохранения и медицинского менеджмента Департамента здравоохранения города Москвы", 2020. с. 146. ISBN: 978-5-907404-04-5.
20. Арболишвили Г.Н., Лысенко М.А., Лысенко С.В. Кардиореанимация. История, эволюция, современность, новые вызовы. Московская медицина. 2020;3(37):54-66. EDN BASZWJ.
21. Thiele H, Ohman E, Desch S, et al. Management of cardiogenic shock. European Heart Journal. 2015;36(20):1223-30. doi:10.1093/eurheartj/ehv051.
22. De Backer D, Creteur J, Dubois M, et al. Microvascular alterations in patients with acute severe heart failure and cardiogenic shock. American Heart Journal. 2004;147(1):91-9. doi:10.1016/j.ahj.2003.07.006.
23. Stenberg T, Kildal, Sanden E, et al. The acute phase of experimental cardiogenic shock is counteracted by microcirculatory and mitochondrial adaptations. PLoS One. 2014;9(9):e105213. doi:10.1371/journal.pone.0105213.
24. Thiele H, Ibrahim A, Sandri M, et al. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. New England Journal of Medicine. 2017;377(25):2419- 32. doi:10.1056/nejmoa1710261.
25. Jung C. Assessment of microcirculation in cardiogenic shock. Current Opinion in Critical Care. 2019;25(4):410-6. doi:10.1097/MCC.0000000000000630.
26. Kohsaka S, Menon V, Lowe A, et al. Systemic Inflammatory Response Syndrome After Acute Myocardial Infarction Complicated by Cardiogenic Shock. Arch Intern Med. 2005;165(14):1643-50. doi:10.1001/archinte.165.14.1643.
27. Prondzinsky R, Unverzagt S, Lemm H, et al. Interleukin-6, -7, -8 and -10 predict outcome in acute myocardial infarction complicated by cardiogenic shock. Clinical Research in Cardiology. 2012;101(5):375-84. doi:10.1007/s00392-011-0403-3.
28. Parenica J, Jarkovsky J, Malaska J, et al. Infectious complications and immune/ inflammatory response in cardiogenic shock patients: A prospective observational study. Shock. 2017;47(2):165-74. doi:10.1097/SHK.0000000000000756.
29. Hochman JS, Sleeper LA, Godfrey E, et al. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock: An international randomized trial of emergency PTCA/ CABG-trial design. American Heart Journal. 1999;137(2):313-21. doi:10.1053/hj.1999.v137.95352.
30. Reynolds HR, Anand SK, Fox JM, et al. Restrictive physiology in cardiogenic shock: Observations from echocardiography. American Heart Journal. 2006;151(4):890.e9-890. e15. doi:10.1016/j.ahj.2005.08.020.
31. Jacobs AK, Leopold JA, Bates E, et al. Cardiogenic shock caused by right ventricular infarction: A report from the SHOCK registry. Journal American College Cardiology. 2003;41(8):1273-9. doi:10.1016/S0735-1097(03)00120-7.
32. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal. 2021;42(14):1289-367. doi:10.1093/eurheartj/ehaa575.
33. Henry TD, Tomey MI, Tamis-Holland JE, et al. Invasive Management of Acute Myocardial Infarction Complicated by Cardiogenic Shock A Scientific Statement From the American Heart Association. Circulation. 2021;143(15):e815-e829. doi:10.1161/CIR.0000000000000959.
34. Wijns W, Naber CK. Reperfusion delay in patients with high-risk ST-segment elevation myocardial infarction: Every minute counts, much more than suspected. European Heart Journal. 2018;39(13):1075-7. doi:10.1093/eurheartj/ehy069.
35. Levy B, Buzon J, Kimmoun A. Inotropes and vasopressors use in cardiogenic shock: When, which and how much? Current Opinion in Critical Care. 2019;25(4):384-90. doi:10.1097/MCC.0000000000000632.
36. Nativi-Nicolau J, Selzman CH, Fang JC, Stehlik J. Pharmacologic therapies for acute cardiogenic shock. Current Opinion in Cardiology. 2014;29(3):250-7. doi:10.1097/HCO.0000000000000057.
37. Papp Z, Édes I, Fruhwald S, et al. Levosimendan: Molecular mechanisms and clinical implications: Consensus of experts on the mechanisms of action of levosimendan. International Journal of Cardiology. 2012;159(2):82-7. doi:10.1016/j.ijcard.2011.07.022.
38. Lewis TC, Aberle C, Altshuler D, et al. Comparative Effectiveness and Safety Between Milrinone or Dobutamine as Initial Inotrope Therapy in Cardiogenic Shock. Journal of Cardiovascular Pharmacology and Therapeutics. 2019;24(2):130-8. doi:10.1177/1074248418797357.
39. Westfall TС, Westfall DP. Adrenergic agonists and antagonists. In: Brunton L. L., & Chabner B.A., & Knollmann B.C. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 12e. McGraw Hill. ISBN 978-0-07-162442-8.
40. De Backer D, Biston P, Devriendt J, et al. SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. New England Journal of Medicine. 2010;362(9):779-89. doi:10.1056/NEJMoa0907118.
41. Karami M, Hemradj VV, Ouweneel DM, et al. Vasopressors and inotropes in acute myocardial infarction related cardiogenic shock: A systematic review and meta-analysis. Journal of Clinical Medicine. 2020;9(7):1-12. doi:10.3390/jcm9072051.
42. Ramteke H, Walke V. Management of advanced stage heart failures by mechanical circulatory supportive devices: current technologies and future perspectives. Life Research. 2022;5(3):2.
43. Schrage B, Ibrahim K, Loehn T, et al. Impella support for acute myocardial infarction complicated by cardiogenic shock: Matched-pair iabp-shock II trial 30-day mortality analysis. Circulation. 2019;139(10):1249-58. doi:10.1161/CIRCULATIONAHA.118.036614.
44. Ouweneel DM, Schotborgh JV, Limpens J. Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. Intensive Care Medicine. 2016;42(12):1922-34. doi:10.1007/s00134-016-4536-8.
45. Vallabhajosyula S, Kashani K, Dunlay SM. Acute respiratory failure and mechanical ventilation in cardiogenic shock complicating acute myocardial infarction in the USA, 2000-2014. Ann Intensive Care. 2019;9(1):96. doi:10.1186/s13613-019-0571-2.
46. Ronco C, Bellomo R. Dialysis in intensive care unit patients with acute kidney injury: Continuous therapy is superior. Clinical Journal of the American Society of Nephrology. 2007;2(3):597-600. doi:10.2215/CJN.00430107.